Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138572

Published: 2020

Journal Articles

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem Solh, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 2006.

https://doi.org/10.1182/blood-2019-123230

Published: 2019

Journal Articles

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2019) 134 (Supplement_1): 2014.

https://doi.org/10.1182/blood-2019-125229

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score

Melhem Solh, MD, Dawn Speckhart, PhD, Xu Zhang, PhD, Asad Bashey, MD PhD, Scott R. Solomon, MD, Lawrence E Morris, MD, H. Kent Holland, MD

Blood (2019) 134 (Supplement_1): 3493.

https://doi.org/10.1182/blood-2019-131639

Published: 2019

Journal Articles

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Blood (2019) 134 (Supplement_1): 4525.

https://doi.org/10.1182/blood-2019-129488

Published: 2019

Journal Articles

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy

Melhem Solh, MD, Xu Zhang, PhD, Asad Bashey, MD PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 4541.

https://doi.org/10.1182/blood-2019-131661

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Melhem Solh, MD, Scott R. Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 4479.

https://doi.org/10.1182/blood-2019-131624

Published: 2019

Journal Articles

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

Eva Karam, PharmD, Justin LaPorte, PharmD, Connie Sizemore, PharmD, Xu Zhang, PhD, H. Kent Holland, MD, Melhem Solh, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 3269.

https://doi.org/10.1182/blood-2019-131365

Published: 2019

Journal Articles

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies

Melhem Solh, MD, Scott R. Solomon, MD, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 3333.

https://doi.org/10.1182/blood-2019-131608

Published: 2019

Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD

Blood (2019) 134 (Supplement_1): 1591.

https://doi.org/10.1182/blood-2019-130449

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of Unselected Elderly Acute Myeloid Leukemia (AML) Patients Referred to a Combined Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

Scott R Solomon, MD, Katelin C Jackson, Xu Zhang, PhD, Melhem Solh, MD, Asad Bashey, MD PhD, H. Kent Holland, MD, Lawrence E Morris, MD

Blood (2018) 132 (Supplement 1): 2675.

https://doi.org/10.1182/blood-2018-99-111048

Published: 2018

Journal Articles

The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease

Melhem Solh, MD, Scott R Solomon, MD, Lawrence E Morris, MD, H. Kent Holland, MD, Xu Zhang, PhD, Asad Bashey, MD PhD

Blood (2018) 132 (Supplement 1): 82.

https://doi.org/10.1182/blood-2018-99-118789

Published: 2018

Journal Articles

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Blood (2018) 132 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2018-99-117231

Published: 2018

Journal Articles

Transplant Rates and Outcomes of Young Acute Myeloid Leukemia (AML) Patients with Intermediate and Poor Risk Disease Referred to a Coordinated Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

Melhem Solh, MD, Xu Zhang, PhD, Asad Bashey, MD PhD, Lawrence E Morris, MD, Zain Bashey, H. Kent Holland, MD, Scott R Solomon, MD

Blood (2018) 132 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2018-99-119185

Published: 2018

Journal Articles

Class II HLA Epitope Level Mismatch Can Predict Chronic Graft-Versus-Host Disease and Survival Following Haploidentical Transplant Using Post-Transplant Cyclophosphamide

Scott R Solomon, MD, Michael T Aubrey, CHS, Cheri Anobile, Xu Zhang, PhD, Brian M Freed, PhD DABHI, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem Solh, MD, Asad Bashey, MD PhD

Blood (2018) 132 (Supplement 1): 311.

https://doi.org/10.1182/blood-2018-99-114122

Published: 2018

Journal Articles

Long-Term Follow-up of Myeloablative Haploidentical (HID) Peripheral Blood Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) Following Fludarabine and Total Body Irradiation (TBI)

Scott R Solomon, MD, Xu Zhang, PhD, Melhem Solh, MD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2018) 132 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2018-99-111029

Published: 2018

Journal Articles

Myeloablative Hematopoietic Cell Transplantation (HCT) for Low and Intermediate Disease Risk Index Myeloid Malignancies Results in Better Outcomes Compared to Reduced Intensity HCT

Melhem M Solh, MD, Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R Solomon, MD

Blood (2017) 130 (Supplement 1): 2050.

https://doi.org/10.1182/blood.V130.Suppl_1.2050.2050

Published: 2017

Journal Articles

Identifying Risk Factors for Acute and Chronic Graft-Versus-Host Disease in T-Replete HLA-Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Jimena Baron, Michelle Ridgeway, Xu Zhang, PhD, Asad Bashey, MD PhD, Scott R Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Melhem M Solh, MD

Blood (2017) 130 (Supplement 1): 1977.

https://doi.org/10.1182/blood.V130.Suppl_1.1977.1977

Published: 2017

Journal Articles

Easy-to-Read Informed Consent (ETRIC) Form for Hematopoietic Cell Transplantation (HCT) Clinical Trials: Results from Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1205 Study

Navneet S. Majhail, MD MS, Sergey Tarima, PhD, Ellen Denzen, MS, Heather Moore, MPH, Sunil Abhyankar, MD, Peter Dawson, PhD, Amy Foley, Iris D. Gersten, MS, Mitchell E. Horwitz, MD, Lensa Idossa, MPH, Steven Joffe, MDMPH, Naynesh Kamani, MD, Roberta King, MPH, Aleksandr Lazaryan, MD PhD MPH, Lawrence E Morris, MD, Mary M. Horowitz, MD MS, Ryan Spellecy, PhD

Blood (2017) 130 (Supplement 1): 4687.

https://doi.org/10.1182/blood.V130.Suppl_1.4687.4687

Published: 2017

NARROW

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score

Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Treatment Patterns and Outcomes of Unselected Elderly Acute Myeloid Leukemia (AML) Patients Referred to a Combined Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Transplant Rates and Outcomes of Young Acute Myeloid Leukemia (AML) Patients with Intermediate and Poor Risk Disease Referred to a Coordinated Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program

Class II HLA Epitope Level Mismatch Can Predict Chronic Graft-Versus-Host Disease and Survival Following Haploidentical Transplant Using Post-Transplant Cyclophosphamide

Long-Term Follow-up of Myeloablative Haploidentical (HID) Peripheral Blood Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) Following Fludarabine and Total Body Irradiation (TBI)

Myeloablative Hematopoietic Cell Transplantation (HCT) for Low and Intermediate Disease Risk Index Myeloid Malignancies Results in Better Outcomes Compared to Reduced Intensity HCT

Identifying Risk Factors for Acute and Chronic Graft-Versus-Host Disease in T-Replete HLA-Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Easy-to-Read Informed Consent (ETRIC) Form for Hematopoietic Cell Transplantation (HCT) Clinical Trials: Results from Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1205 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only